Last week, Boehringer Ingelheim announced that it had enrolled the first patient into its VOLTAIRE-X interchangeability study. This Phase 3 study will investigate the interchangeability of BI’s adalimumab biosimilar candidate, BI 695501, and Humira® in patients with moderate-to-severe chronic plaque psoriasis. According to BI, results from this study are expected in the second half of 2019.
The post Boehringer Ingelheim Announces Start Of Adalimumab Biosimilar Interchangeability Study appeared first on Big Molecule Watch.